在实践中导航药物基因组学检测:谁检测与何时检测
本文探讨药物基因组学(PGx)检测在个体化用药中的临床应用价值。多数专业学会指南不推荐常规PGx检测,仅少数例外;指南、FDA标签与支付政策不一致阻碍了检测推广。文章讨论检测需考虑的多种因素,并比较了先发筛查、治疗前检测和反应性检测三种模式的优缺点,提出在当前真实世界中识别PGx检测候选者的观点。
要点
- 多数临床指南不推荐常规PGx检测,仅少数关键例外。
- 指南、FDA标签与支付政策不一致是检测推广的主要障碍。
- 选择检测对象需综合考虑可操作结果频率、不良结局严重性、预测力、替代治疗、成本和周转时间。
核心结论
- PGx检测的临床推广受指南、FDA标签和支付政策不一致的阻碍。
- 回答谁检测与何时检测需综合考虑药物-基因交互临床有效性之外的多种因素。
研究设计与样本
- 本文为观点性文章,讨论PGx检测的考虑因素与检测模式。
主要发现
- 多数专业学会指南不推荐常规PGx检测,仅少数关键例外。
- PGx检测推广受指南、FDA标签和支付政策不一致的阻碍。
- 现有资源多未提供谁应接受PGx检测及何时检测的指导。
- 检测模式包括先发筛查、治疗前检测和反应性检测,各有优缺点。
关键数值与推荐
- 选择检测对象需考虑可操作结果频率、不良临床结局严重性、PGx检测预测力、替代治疗适宜性、成本和结果周转时间。
临床怎么用
- 在真实世界环境中识别PGx检测候选者需综合上述多种因素,并与理想临床场景区分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions. Inconsistent recommendations across clinical practice guidelines, FDA product labeling, and payer reimbursement policies have hampered widespread adoption of testing. Multiple resources exist to aid in the adoption and use of actionable PGx test results in clinical practice; however, most of these resources do not provide guidance on who should receive PGx testing and when-a critical question the clinical community continues to struggle with. There are multiple considerations when answering this question beyond the clinical validity of the drug-gene interaction itself, such as the actionable result frequency, severity of the adverse clinical outcome, predictive power of the PGx test, suitability of alternative treatments, cost, and turnaround time of test results. This perspective discusses these considerations and models for testing including preemptive screening, pretreatment testing, and reactive testing, highlighting advantages and disadvantages of each approach. The authors provide their perspectives on identifying candidates for PGx testing in the current real-world environment and how that differs from a clinically ideal scenario.
引用
- Stevenson JM, Smith DM, Tuteja S, et al. Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test. Clin Pharmacol Ther. 2025. PMID: 40325943. doi:10.1002/cpt.3704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。